Moderna, Inc. ADR (MRNA)

Profile

https://www.modernatx.com

Moderna, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of medicines based on messenger RNA technology. Its primary purpose is to translate genetic instructions into therapeutic proteins inside the body, enabling vaccines and treatments that can be designed and manufactured with speed and scale. The company’s marketed products include a COVID-19 vaccine and a vaccine for respiratory syncytial virus, reflecting its initial commercial focus in infectious diseases while advancing a broad pipeline in areas such as influenza, cytomegalovirus, and other viral pathogens, as well as oncology applications like individualized cancer vaccines. Beyond vaccines, Moderna explores mRNA-based therapeutics for rare diseases and immunology, leveraging a modular platform, in-house manufacturing, and global collaborations to accelerate clinical development. Within the financial market, Moderna represents a platform-driven biotech model where valuation and risk are closely tied to clinical milestones, regulatory outcomes, and the scalability of mRNA manufacturing. Its role is significant as a pioneer of mRNA modalities, shaping industry standards for rapid vaccine development and expanding the potential of programmable medicines across multiple therapeutic areas.